BioSpace News Archive

For the third year, on Oct. 26, SMU Cox Caruth Institute for Entrepreneurship named Intuitive Health- the national leader in dual ER and Urgent Care models-to its coveted list of Dallas 100 companies.

74% of patients treated with CLARIX® FLO demonstrated clinically significant improvement at 12 months, signifying its potential in delaying Total Knee Arthroplasty (TKA)

FINTEPLA® (fenfluramine) oral solution launched in the U.S. in late July for Dravet syndrome with high enrollment of physicians and patients into the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS) program

Editas Medicine, Inc., a leading genome editing company, announced that management will present at Barclays Gene Editing & Gene Therapy Summit on Monday, November 16 at 10:15am ET.

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), today announced that Inspire therapy will be integrated into the German hospital reimbursement system (“G-DRG”), effective January 1, 2021

Sientra, Inc., a global medical aesthetics company, announced that Ron Menezes, former President and General Manager for Almirall Inc., will join Sientra as President and Chief Executive Officer of Sientra, Inc., effective November 10, 2020.

Progenity, Inc., a biotechnology company with an established track record of success in developing and commercializing molecular testing products, provided corporate updates and reported financial results for the third quarter ended September 30, 2020.

Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2020.

Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its third quarter 2020 financial results, program progress and corporate updates.

Amgen (NASDAQ:AMGN) today announced that data from its cardiovascular (CV) portfolio will be presented at the American Heart Association (AHA) Scientific Sessions 2020: A Virtual Experience, Nov. 13-17, 2020.